Literature DB >> 16809543

Intron removal requires proofreading of U2AF/3' splice site recognition by DEK.

Luis Miguel Mendes Soares1, Katia Zanier, Cameron Mackereth, Michael Sattler, Juan Valcárcel.   

Abstract

Discrimination between splice sites and similar, nonsplice sequences is essential for correct intron removal and messenger RNA formation in eukaryotes. The 65- and 35-kD subunits of the splicing factor U2AF, U2AF65 and U2AF35, recognize, respectively, the pyrimidine-rich tract and the conserved terminal AG present at metazoan 3' splice sites. We report that DEK, a chromatin- and RNA-associated protein mutated or overexpressed in certain cancers, enforces 3' splice site discrimination by U2AF. DEK phosphorylated at serines 19 and 32 associates with U2AF35, facilitates the U2AF35-AG interaction and prevents binding of U2AF65 to pyrimidine tracts not followed by AG. DEK and its phosphorylation are required for intron removal, but not for splicing complex assembly, which indicates that proofreading of early 3' splice site recognition influences catalytic activation of the spliceosome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809543     DOI: 10.1126/science.1128659

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  83 in total

1.  CEF1/CDC5 alleles modulate transitions between catalytic conformations of the spliceosome.

Authors:  Charles C Query; Maria M Konarska
Journal:  RNA       Date:  2012-03-08       Impact factor: 4.942

2.  C/EBPα and DEK coordinately regulate myeloid differentiation.

Authors:  Rositsa I Koleva; Scott B Ficarro; Hanna S Radomska; Marlene J Carrasco-Alfonso; John A Alberta; James T Webber; C John Luckey; Guido Marcucci; Daniel G Tenen; Jarrod A Marto
Journal:  Blood       Date:  2012-04-03       Impact factor: 22.113

Review 3.  Proofreading and spellchecking: a two-tier strategy for pre-mRNA splicing quality control.

Authors:  Defne E Egecioglu; Guillaume Chanfreau
Journal:  RNA       Date:  2011-01-04       Impact factor: 4.942

Review 4.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 5.  Diverse regulation of 3' splice site usage.

Authors:  Muhammad Sohail; Jiuyong Xie
Journal:  Cell Mol Life Sci       Date:  2015-09-14       Impact factor: 9.261

6.  MicroRNA-592 targets DEK oncogene and suppresses cell growth in the hepatocellular carcinoma cell line HepG2.

Authors:  Xin Li; Wenfeng Zhang; Liya Zhou; Donghui Yue; Xin Su
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

7.  The DEK nuclear autoantigen is a secreted chemotactic factor.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; Neil Faulkner; Maureen Legendre; Michael S Khodadoust; Ferdinand Kappes; Jeffrey H Ruth; Alisa Koch; David Glass; Lilli Petruzzelli; Barbara S Adams; David M Markovitz
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

8.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.

Authors:  Nirit Mor-Vaknin; Ferdinand Kappes; Amalie E Dick; Maureen Legendre; Catalina Damoc; Seagal Teitz-Tennenbaum; Roland Kwok; Elisa Ferrando-May; Barbara S Adams; David M Markovitz
Journal:  Arthritis Rheum       Date:  2011-02

9.  Multi-domain conformational selection underlies pre-mRNA splicing regulation by U2AF.

Authors:  Cameron D Mackereth; Tobias Madl; Sophie Bonnal; Bernd Simon; Katia Zanier; Alexander Gasch; Vladimir Rybin; Juan Valcárcel; Michael Sattler
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

Review 10.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.